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Cytokine stimulation of prostaglandin production inhibits the prolifer-
ation of serum-stimulated mesangial cells. Mesangial cell proliferation
contributes to glomeruloscierosis and is associated with the develop-
ment of end-stage renal disease. We examined the effects of the
cytokines interleukin 1 (IL-l/3) and interleukin 6 (IL-6) on the mitogen-
esis and proliferation of rat glomerular mesangial cells. Exposure of
serum-stimulated cells to IL-1/3 and IL-6 for 48 hours resulted in a
dose-dependent inhibition of both mitogenesis, determined by 3H-
thymidme incorporation, and proliferation, determined by absolute cell
counts. Both IL-113 and IL-6 stimulated endogenous PGE2 production
in this cell system. Cyclooxygenase inhibition by indomethacin and
meclofenamate abrogated the inhibitory effects of both IL-l/3 and IL-6.
Furthermore, addition of exogenous PGE2 to cytokine-stimulated cells
in which cyclooxygenase activity was blocked resulted in inhibition of
mitogenesis, while addition of exogenous aracidonic acid to the cyto-
kine-stimulated cells enhanced the induced inhibition of mitogenesis.
These results demonstrate that in serum-stimulated mesangial cells,
both IL-l/3 and IL-6 inhibit mitogenesis and proliferation, and that these
effects are mediated, in part, by stimulated endogenous prostaglandin
production.
The pathogenesis of glomerulosclerosis and the progression
to end-stage renal disease has been the focus of abundant
research in the past twenty years. Since the glomerulus and
interstitium can respond to injury in a limited fashion, multiple
immunologic and non-immunologic insults have a final common
pathway—the development of sclerosis. In addition, the dam-
aged kidney has a propensity to contribute further to its own
deterioration. The end-stage or sclerotic kidney, regardless of
underlying cause, has fairly constant findings. In particular, the
glomerulus demonstrates a loss of capillaries, areas of cellular
proliferation, and an increase in matrix deposition [1].
Abundant clinical and experimental evidence supports the
concept that mesangial cell proliferation precedes and presum-
ably contributes to the development of glomerulosclerosis. In
childhood nephrotic syndrome, mesangial hypercellularity is
associated with a poorer response to glucocorticoids and to an
increased risk of the development of focal segmental glomeru-
loscierosis (FSGS) [2, 3]. Fogo et al have recently demonstrated
that children with minimal change nephrotic syndrome with
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evidence of glomerular hypertrophy due presumably to cellular
proliferation, cellular hypertrophy, or expansion of the glomer-
ular matrix, are at increased risk for progression to FSGS [4].
Furthermore, experimental evidence, including the remnant
kidney model [5], and the Thy 1.1 model of mesangial prolifer-
ative glomerulonephritis [6], supports the view that mesangial
cell proliferation precedes glomerulosclerosis.
A recent explosion of research has demonstrated the biologic
effects of the various growth factors—peptides which modulate
glomerular cellular proliferation, matrix synthesis, develop-
ment and diferentiation, immunoinflammatory responses, and
changes in vascular tone [7]. In addition to their effects on
glomerular hemodynamics and tubular function, prostaglandins
also likely modulate and play a role in mesangial cell prolifer-
ation. As has been demonstrated in cultured vascular smooth
muscle cells, incubation with indomethacin enhances IL-l
induced proliferation [8]. Prostaglandins of the A and E series
have been shown to exert potent antimitogenic effects in
various cell lines including macrophages, human melanoma,
and various tumor cell lines [9—11]. Studies with mesangial cells
have demonstrated an antimitogenic effect of the thromboxane
(TXA2) agonist U46619 [12], and of the prostacycin (PGI2)
analogue Iloprost in serum-stimulated cells [13].
The objectives of this study were twofold: first, to study the
effects of the cytokines IL-1f3 and IL-6 on the proliferation of
serum-stimulated mesangial cells; and second, to study the role
of stimulated mesangial cell prostaglandins in this process.
Methods
Cell culture
Rat glomerular mesangial cells were isolated by a differential
sieving technique modified from Hassid et al (Am J Physiol
251 :F1018—F1028, 1986). Male Sprague-Dawley rats weighing
between 150 to 200 g were used for all experiments. For each
cell culture four to eight rats were anesthetized with ether, their
kidneys aseptically removed, and collected immediately in
sterile Hanks balanced salt solution (HBSS, Sigma Chemical
Co., St. Louis, Missouri, USA). The kidneys were then decap-
sulated, sectioned sagitally, and the cortical tissue dissected
carefully from the medulla. This tissue was then minced into a
paste-like consistency, then filtered and washed through a 149
sm Spectramesh® filter (Spectrum Medical Industries, Los
Angeles, California). The filtrate containing intact glomerular
cores was collected, triturated, and then filtered through a 70
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m Spectramesh® filter. The glomerular cores were washed off
the filter and collected in RPMI-1640 cell culture media (Sigma).
The cores were then washed in RPMI-1640 and incubated with
collagenase Type IV (Sigma) 750 U/mi for five minutes in a 37°C
shaking water bath. Glomerular cores were then plated onto
sterile 60 mm tissue culture plates (Corning, New York, New
York, USA) in RPMI-1640 supplemented with 15% (vol/vol)
heat inactivated fetal calf serum (Sigma) in addition to insulin 5
g/ml, transferrin 5 p.g/ml, selenium 5 ng/ml in the form of ITSTM
Premix (Collaborative Research, Bedford, Massachusetts,
USA), penicillin 100 U/mi, streptomycin 100 g/ml, and am-
photericin 0.025 g/ml as Hybrimax°M (Sigma). The culture was
maintained in RPMI-1640 with 15% FCS, ITS, and antibiotics in
a humidified incubator with ambient 95% 02 and 5% CO2. The
cell culture medium was changed every two to three days, and
after reaching confluence in 21 to 30 days, the cells were
trypsinized with EDTA-trypsin (5 g trypsin 1:250 2 g EDTA 4
Na/liter) (Sigma) and transferred to 75 cm2 tissue culture flasks.
Cells were then passaged every 10 to 14 days. Cells from
passages 2 through 12 were used in the cell proliferation
experiments, while cells from passages 2 through 3 were used
for the PGE2 experiments.
After day 8 of the initial culture, cells were incubated
overnight with puromycin aminonucleoside (10 g/ml, Sigma),
which is differentially toxic to glomerular epithelial cells. The
cells were further characterized by their typical spindle-shape
with abundant intracellular myofilaments on phase-contrast
microscopy (Biostar, AO Scientific Instruments). In addition,
the cells demonstrated dramatic positive immunoperoxidase
staining with monoclonal antibodies to rat smooth muscle actin
and desmin, and negative staining with factor VIII antigen.
Functionally they demonstrated contraction upon incubation
with angiotensin II (Sigma), as described by Kreisberg (Fed
Proc 42:3053—3057, 1983).
Cell proliferation assay
Mesangial cells from passages 2 through 12 were used for
3H-thymidine incorporation experiments. Cells were removed
from the flask surfaces by first washing with HBSS (without
calcium and magnesium) and then with trypsin-EDTA at 37°C
until the cells had visibly detached from the flask surface (5 to
10 minutes). The cells were then plated in 25 cm2 tissue culture
flasks and allowed to grow to confluence over 10 to 14 days,
changing the media every two to three days. These cells were
then trypsinized in a similar manner and resuspended in RPM!-
1640 and 15% FCS (with ITSTM Premix and tlybrimaxTM antibi-
otics) to a cell density of 5-10 x lO cells/ml. Ninety-six well
tissue culture plates (Falcon, Lincoln Park, New Jersey, USA)
were plated at this density and left for 12 hours to ensure
adherence. The media were then aspirated and the cells washed
with HBSS (with Ca and Mg) and grown in serum-free medium
(SFM) for 72 hours to arrest cell growth and synchronize the
cells in the GO/Gi phase of mitosis. After 72 hours of serum-free
conditions the cells were washed and then incubated with the
various agents for 36 hours, after which 0.5 sCi of 3H-thymi-
dine (Amershan, Arlington Heights, illinois, USA) was added
to each well. Using an automated cell harvester (Whittaker
Bioproducts Inc., Walkersvile, Missouri, USA) the cells were
harvested 18 hours after the addition of the thymidine, and
thymidine incorporation measured using a Packard 2000 CA
scintillation counter (Packard Instruments, Sterling, Virginia,
USA).
For the cell counting experiments cells were plated in 24 well
tissue culture plates (Falcon) at a density of 0.5 to 1 x iO
cells/well. After 18 hours the cells were washed and then grown
in SFM for 72 hours, after which the various stimuli were
added. After exposure to the various agents for 48 hours, the
media were aspirated and the cells gently removed from the
flask surface with EDTA-trypsin. The cells were then resus-
pended in 1 ml of RPMI-1640 and 15% FCS and counted
manually using a hemocytometer (American Scientific Prod-
ucts).
The various agents used to stimulate the cells included
recombinant human IL-113, IL-6, platelet derived growth factor
(PDGF) (R & D Systems, Minneapolis, Minnesota, USA),
concanavalIn A (Con A), POE2, indomethacin, meclofenamate
(Sigma), and arachidonic acid (Cayman Chemical Co, Minne-
apolis, Minnesota, USA). These agents alone and in combina-
tion were dissolved in RPMI-1640 supplemented with either
SFM or 15% FCS.
PGE2 measurement
Cells were plated in 24 well tissue culture plates at a density
of 0.5 to 1 x iO cells/mi. After 18 hours the cells were washed
and maintained in SFM supplemented RPMI-1640 for 72 hours.
After 72 hours of quiescence cells were washed and then
stimulated with the various agents. Parallel experiments were
performed and the quantity of POE2 in the cell supernatant was
measured at various time intervals using an enzyme immuno-
assay (Cayman Chemical Co.). Briefly, the assay is a compet-
itive EIA between free POE2 and acetylcholinesterase-linked
PGE2 for a rabbit anti-POE2 antibody. Microtiter plates coated
with a mouse anti-rabbit IgG monoclonal antibody bind the
anti-PGE2-PGE2 complex (with or without tracer), and the
quantity of bound tracer is determined colorimetrically by the
addition of Ellman's reagent (acetythiocholine is hydrolyzed to
thiocholine which reacts 5,5'-dithio-bis-(2-nitrobenzoic acid) to
produce 5-thio-2-nitrobenzoic acid). The intensity of the color
change is inversely proportional to the concentration of free
POE2 in the sample. The sensitivity of the assay is to 4 to 8 pg
PGE2/ml sample with 100% specificity for PGE2 and 9.2% for
15-keto PGE2.
Cell protein content was determined using a modification of
the standard Lowry assay. Results were expressed as ng
PGE2/g of cell protein, using BSA (Sigma) as the protein
standard.
Statistical analysis
For the thymidine uptake measurements each experiment
was performed between three to eight times. Uptake was
measured in triplicate wells and expressed as percent of appro-
priate control. For the cell counting, triplicate wells were
counted in at least three separate experiments. For POE2
production experiments, a minimum of three experiments was
performed in triplicate wells. POE2 measurements from sam-
ples were performed in duplicate at two dilutions per sample.
The results were analyzed using analysis of variance and
two-sided Student's t-test where appropriate. The commercial
statistical software package Statview 512+ (Calabasa, Califor-
nia, USA) was utilized on a personal Macintosh computer.
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Results
To demonstrate the proliferative and mitogenic capacity of
this mesangial cell system, we incubated the cells with increas-
ing concentrations of fetal calf serum (FCS). Thymidine incor-
poration increased in a dose-dependent manner. Stimulation
with 15% FCS resulted in a threefold increase in mitogenesis
compared to serum-free conditions—while coincubation with
Con A and PDGF augmented this to 350 and 400%,respectively
(data not shown).
Incubation of the serum-stimulated cells with IL-l/3 and IL-6
inhibited mitogenesis in a dose-dependent fashion and in the
absence of significant cytotoxicity (Fig. 1A). A more dramatic
response was achieved with similar concentrations of IL-i f3.
The parallel cell counting experiments resulted in a similar
inhibition of proliferation of serum-stimulated cells for both
IL-1/3 and IL-6, in both cases maximally to 50% control (Fig.
lB).
To explain this somewhat unexpected cytokine inhibition of
serum-stimulated mesangial cell mitogenesis and proliferation,
we studied the role of stimulated endogenous prostaglandin
production, based upon its well-described inhibitory properties
in other cell lines. We postulated that stimulation of the cells
with IL-1f3 and IL-6 would affect the production of endogenous
POE2, which might play an inhibitory role on cell proliferation
in stimulated cells.
In these experiments, PGE2 production was measured in the
cell supernatant at various time intervals (Fig. 2). There was no
significant increase in basal, unstimulated production of PGE2
over a 48 hour period. Stimulation of the cells with IL-6, in a
concentration of 10 ng/ml, resulted in a significant increase over
basal conditions, evident as early as 12 hours after stimulation,
Stimulation of the cells with IL-l/3, also in a concentration of 10
ng/ml, resulted in a dramatic increase in POE2 production over
basal conditions—again evident at the 12 hour timepoint. The
calculated range of concentrations of POE2 in these cytokine-
stimulated experiments, based upon the average cell protein
concentration of the wells, was 2 x l0 to 1.3 x l0 M.
Notably, coincubation of the cells with idomethacin effectively
extinguished any stimulated POE2 production.
To test the hypothesis that this stimulated prostaglandin
production contributes to the inhibition of serum-stimulated
mitogenesis, we incubated the cells with the cyclooxygenase
inhibitors indomethacin and meclofenamate. In this set of
experiments we again saw a dose-dependent inhibition in mito-
genesis and proliferation by IL-lf3. When the cells were incu-
bated with indomethacin at a concentration of 1 sglml, which
inhibits endogenous POE2 production, the inhibitory effect of
IL-1f3 was blocked at all concentrations. The same effect was
achieved by incubating the cells with meclofenamate at a
concentration of 10—6 M (Fig. 3A). Similar results were
achieved with IL-6. In these experiments, IL-6 again inhibited
serum stimulated mitogenesis and proliferation, but coincuba-
tion with either indomethacin or meclofenamate blocked this
effect and restored mitogenesis to control values (Fig. 3B).
To further incriminate prostaglandins in the inhibition of
serum-stimulated mitogenesis and proliferation, we looked at
the effect of adding exogenous POE2 to our cell system.
Exposing serum-stimulated mesangial cells to exogenous PGE2
resulted in a dose-dependent inhibition of 3H-thymidine incor-
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Fig. 1. A. Cytokine inhibition ofcultured rat mesangial cell mitogen-
esis. Percent decreases in [3H]-thymidine incorporation after incubation
with IL-113 (0) and IL-6 (0) in 15% FCS after 48 hours. Control
experiments with 15% FCS, in absence of cytokines. Mean SE of N
= 6 experiments, *J) < 0.05 vs. control. B. Cytokine inhibition of
cultured rat mesangial cell proliferation. Percent decreases in absolute
cell number after incubation with IL-1/3 (0) and IL-6 (D) in 15% FCS
after 48 hours. Control experiments with 15% FCS in absence of
cytokines. Mean SE of N =5 experiments, < 0.05 vs. control.
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Time, hours
Fig. 2. Cytokine stimulated mesangial cell PGE2 production. In-
creases in cell supernatant PGE2 concentration, corrected for cell
protein, over 48 hours for IL-lf3 (10 ng/ml, •), IL-6 (10 ng/ml, 0),
incubated with indomethacin (1 pg/mi, ), and basal, unstimulated
conditions, (U). Data are means SE of N = 3 experiments. *p < 0.05
vs. basal production.
poration (Fig. 4). Maximum inhibition occurred at iO M
POE2, decreasing incorporation to approximately 50% control,
in the absence of cytotoxicity, Concentrations greater than iO—
M POE2 resulted in increasing cell toxicity and death. In these
experiments incubation of the cells with 10—6 M POE2 resulted
in a reduction of 3H-thymidine incorporation to 69% control.
As in the previous experiments, incubating the cytokine-
treated cells with indomethacin restored mitogenesis to control
values (Fig. 5A,B), Addition of exogenous PGE2 (10—6 M) to the
indomethacin treated cells resulted in a further decrease in
mitogenesis at all concentrations of cytokine. This decrease in
serum-stimulated mitogenesis approximated, but was not as
dramatic, as that achieved by the cytokines in the absence of
indomethacin.
Finally, in a seperate set of experiments, we studied the
effects of exogenous arachidonic acid on cytokine-stimulated
cells (Fig. 6). Tn both IL-lp and IL-6 treated cells co-incubation
with arachidonic acid (106 M) potentiated the antimitogenic
effect of the cytokine at all concentrations studied. The differ-
ences were statistically significant at 0.1 nglml for IL-lJ3 and at
10 ng/ml for IL-6.
Discussion
To understand and to be able to interrupt the sequence of
events leading to glomerulosclerosis and end-stage renal dis-
ease, first the nature of the vascular, metabolic, or immunologic
insult which initiates the renal disease should be addressed.
Secondly, the intrarenal processes which persist, even after the
initial insult has been removed, need to be delineated. Mesan-
gial cells participate in the structural and functional changes
that accompany glomerular pathology, both as targets and
effector cells, In this study we have demonstrated an antimito-
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Fig. 3. A. Restoration of mitogenesis in IL-l$ treated mesangial cells
by cyclooxygenase inhibition. Percent changes in [3H]-thymidine incor-
poration with IL-113 (N = 4, 0), IL-1f3 + indomethacin (1 pg/mI, N =
5, 0), and IL-l13 + meciofenamate (10—6 M, N =4, U). Data are means
SE, < 0.05 vs. control (15% FCS). B. Restoration of mitogenesis
in IL-6 treated mesangial cells by cyclooxygenase inhibition. Percent
changes in [3H1-thymidine incorporation with IL-6 (N = 4, 0), IL-6 +
indomethacin (1 pg/mi, N = 5, 0) and IL-6 + meclofenamate (10-6 M,
N = 4, U). Data are mean SE, *p < 0.05 vs. control (15% FCS).
genic effect of both IL-l/3 and IL-6 on mesangial cells stimu-
lated with 15% FCS. Cell proliferation, in response to FCS, was
dose-dependent, with a 300 to 400% increase over control
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values when stimulated with 15% FCS. Nonetheless, the cells
so stimulated were capable of further proliferation, as demon-
strated by the augmented response when incubated with Con A
and PDGF. Interleukin 1, derived from both endogenous and
exogenous cells in the a and /3 forms [14], has been known for
many years to be a comitogen for cultured mesangial cells [15],
in addition to its ability to stimulate PGE2 production [16],
collagen synthesis [17], and IL-8 production [18]. In the case of
IL-la, signaling pathways activated by this peptide alone will
not induce mesangial cell growth [19].
Only recently has limited attention been focused on the role
of IL-6 in mesangial cell proliferation. The first indirect obser-
vation was by Suematsu et al who induced mesangioprolifera-
tive glomerulopathy in mice made transgenic for the human
IL-6 gene [20]. Horii et al extended this observation to demon-
strate increased urinary excretion and glomerular immunolocal-
ization of IL-6 in adult patients with mesangial proliferative
glomerulonephritis [21]. Recently, Ruef et al demonstrated that
mesangial cell-derived IL-6 stimulates the proliferation of me-
sangial cells in serum-deprived (0.5% FCS) conditions [22].
Using recombinant human IL-6, we have demonstrated an
inhibition of mitogenesis and proliferation in cells cultured in
15% FCS, without the addition of insulin, as in the experiments
of Horii et al.
To provide a unifying explanation for this somewhat unex-
pected inhibition of proliferation and mitogenesis, we studied
the role of stimulated endogenous prostaglandin production by
these mesangial cells. Both IL-1j3 and IL-6 stimulated the
production of POE2 by mesangial cells. Prostaglandins of the A
and E series have been shown to be potent inhibitors of
proliferation in a variety of cultured cells [9—11]. In addition, the
cyclooxygenase metabolites TXA2 and PGI2 have been impli-
cated in inhibition of proliferation of serum-stimulated mesan-
gial cells [12, 13]. Interestingly, however, is that the TXA2
agonist U46619 paradoxically stimulates the proliferation of
quiescent, serum-deprived cells [23].
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Fig. 5. A. Inhibition of mesangial cell mitogenesis by exogenous
PGE2. Percent changes in [3H]-thymidine incorporation by incubation
in 15% FCS with IL-ip (N = 5,0), vs. IL-ip + indomethacin (1 &g/ml,
•, N = 4), and IL-ip + indomethacin + POE2 (106 54, N = 4, •). Data
are means SE, < 0.05 vs. control (15% FCS). B. Inhibition of
mesangial cell mitogenesis by exogenous POE2. Percent changes in
[3H)-thymidine incorporation by incubation with IL-6 in 15% FCS (N =
4, 0), vs. IL-6 + indomethacin (1 g/ml, I, N = 5), and IL-6 +
indomethacin + POE2 (106 M, •) (N = 3). Data are means SE,
0.05 vs. control (15% FCS).
Exogenous POE2 inhibited serum-stimulated mesangial cell
mitogenesis in a dose-dependent fashion. To also study the
effects of both basal and stimulated endogenous prostaglandin
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Fig. 4. PGE2 inhibition of serum-stimulated mesangial cell mitogene-
sis. After 72 hours of serum-free conditions cells were incubated with
15% FCS and increasing concentrations of POE2. [3H]-thymidine incor-
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of serum-stimulated cells, exogenous POE2 inhibited cells in-
cubated with 15% FCS and indomethacin, both in the presence
and absence of cytokine stimulation. This inhibition of mito-
genesis and proliferation approximated but was not as pro-
nounced as the maximal effect of IL-lp or IL-6, indicating only
a partial role of PGE2 in the antimitogenic effect; presumably
additional factors, including the cyclooxygenase metabolites
PGI2, PGA2, stimulated nitric oxide production and other local
peptides, play an additive role in this inhibition of proliferation.
Although the effect of exogenous arachidonate was not dra-
matic, the enhancement of cytokine-inhibition was both consis-
tent and reproducible. The precise mechanism through which the
cytokines stimulate prostaglandin production and consequently
inhibit cell proliferation and mitogenesis was not addressed by this
work. However, the increase in cytokine-induced inhibition by
exogenous arachidonate suggests cytokine stimulation of the
activity and mass of the inducible prostaglandin endoperoxide
synthase enzyme, responsible for the conversion of arachidonic
acid to prostaglandin H2, as previously demonstrated by others
[24]. The limited effects of exogenous arachidonate may have
resulted from cytokine activation of phospholipase A2 with
mobilization of adequate endogenous arachidonate [19] to pro-
vide substrate for the induced prostaglandin synthase activity.
The inhibition of mesangial cell proliferation and mitogenesis by
POE2 is undoubtedly a receptor-mediated event. Transduction
of this receptor signal is likely mediated through the adenylate
cyclase pathway, and, as in other cell systems [25, 26] may be
dependent on the entry of the cells into the G1 phase of mitosis.
Further work is needed to clarify the class and selectivity of
ftinctional PG receptors employed in this inhibition of prolifer-
ation and the factors which modulate their expression and
binding properties.
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